The limited evidence for the efficacy of Aduhelm raises the question of whether its large impact on health spending is justified.

The U.S. Food and Drug Administration recently approved a new drug for treatment of Alzheimer's disease, despite concerns about both the cost and efficacy.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
Core and Group Health
Employer-Paid
Retirement Trends